艾迪联合FOLFOX4方案对结肠癌患者疗效及对术后免疫功能及炎性反应的影响

doi:10.3969/j.issn.1006-6233.2017.06.022

摘要
图/表
参考文献(18)
相关文章 (14)

全文: PDF (1421 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究艾迪联合FOLFOX4化疗方案对结肠癌患者疗效及对术后免疫功能及炎性反应的影响。方法: 选取我院结肠癌患者59例,随机划分为实验组及对照组。对照组28例,手术治疗后予FOLFOX4化疗治疗;实验组31例,予手术治疗后加用艾迪注射液联合FOLFOX4化疗。对比两组的临床疗效及治疗前后患者的免疫功能及炎性反应。结果: 实验组治疗总有效率93.5%高于对照组78.6%,差异存在统计学意义(P<0.05);与对照组对比,实验组患者的毒副反应发生率较低,差异有统计学意义(P<0.05);实验组T淋巴细胞亚群水平较高,差异有统计学意义(P<0.05);实验组IgA,IgG及IgM水平较高,IL-6水平较低,差异有统计学意义(P<0.05)。结论: 艾迪联合FOLFOX4治疗结肠癌患者能减少免疫系统的功能损伤,临床效果良好,同时极大地提高了患者的生活质量,减轻炎性反应。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	宋飞

关键词 ： FOLFOX4, 艾迪注射液, 结肠癌, 免疫功能, 炎性反应

Abstract：Objective: To investigate the effect of Addie combined with FOLFOX4 in the treatment of colon cancer and its effect on immune function and inflammatory reaction. Method: 59 patients with colon cancer in our hospital were randomly divided into the experimental group and the control group. In the control group, 28 cases were treated with FOLFOX4 chemotherapy after operation, while 31 cases in the experimental group was treated with Addie injection combined with FOLFOX4 chemotherapy after operation. The clinical efficacy of the two groups and the immune function and inflammatory reaction before and after treatment were compared. Results: The total effective rate of the experimental group was 93.5% higher than that of the control group (78.6%), and the difference was statistically significant (P<0.05); Compared with the control group, the incidence of side effects was lower in the experimental group, the difference was statistically significant (P<0.05); The levels of IgA, IgG and IgM in the experimental group were higher, and the level of IL-6 was lower, the difference was statistically significant (P<0.05). Conclusion: Addie combined with FOLFOX4 in the treatment of colon cancer patients can reduce the damage to the immune system function, clinical effect is good, and greatly improved the quality of life of patients, reduce inflammatory response.

Key words： FOLFOX4 Addie injection Colon cancer Immune function Inflammatory response

基金资助:山东省自然科学基金,(编号:ZR2015HL130)

引用本文:

宋飞. 艾迪联合FOLFOX4方案对结肠癌患者疗效及对术后免疫功能及炎性反应的影响[J]. 河北医学, 2017, 23(6): 955-958.
SONG Fei. Effect of Addie Combined with FOLFOX4 in the Treatment of Colon Cancer and its Effect on Immune Function and Inflammatory Reaction. 河北医学, 2017, 23(6): 955-958.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2017.06.022 或 http://www.hbyxzzs.cn/CN/Y2017/V23/I6/955

[1] 陈发玲,徐伟珏,李龙至,等.不同病变范围新生儿坏死性小肠结肠炎手术干预效果分析[J].中华实用儿科临床杂志,2016,31(23):1783~1786.
[2] 陶金华,王征,刘正,等.晚期结肠癌转化治疗后行右半结肠切除1例[J].中华结直肠疾病电子杂志,2016,5(1):82~83.
[3] 单君.加速康复护理在结肠癌患者围手术期中应用的临床效果[J].中国基层医药,2016,23(24):3701~3704.
[4] 李娟娟,郑春茂,武爱娣.2015年医院抗肿瘤中药注射剂临床应用分析[J].中国药业,2016,25(16):75~77.
[5] 单君.加速康复护理在结肠癌患者围手术期中应用的临床效果[J].中国基层医药,2016,23(24):3701~3704.
[6] 陈平,袁晓琴,谢玲,等.上海市嘉定地区1265例结肠直肠息肉内镜下诊治临床资料回顾性分析[J].胃肠病学和肝病学杂志,2016,25(5):524~528.
[7] 袁炜嗣,庄丹,林锡汉,等.腹腔镜与传统开腹手术在结肠癌根治术中治疗近期疗效观察[J].黑龙江医学,2016,29(6):1210~1212.
[8] 米希茂,MiXimao.Ⅱ~Ⅲ期大肠癌根治术后两种辅助化疗方案临床疗效及安全性比较[J].中国基层医药,2016,23(6):867~869.
[9] 张腾腾,杨振.康艾注射液体外对结肠癌Lovo细胞凋亡和增殖的影响[J].中国基层医药,2016,23(16):2425~2428.
[10] 王俊芳,张琴,毛莉,等.腹腔内贝伐珠单抗联合腹腔热灌注化疗治疗卵巢癌腹腔积液的疗效和安全性[J].中国基层医药,2016,23(8):1228~1231.
[11] 祁峰,陈苏蓉,尹存林,等.临床药师干预对抗肿瘤药物临床合理应用的影响[J].中国基层医药,2017,24(3):358~364.
[12] 何玲,张倩倩,吕晓云,等.丹参水提液对染镉大鼠血清超氧化物歧化酶、丙二醛、总抗氧化能力的影响[J].中国基层医药,2016,23(23):3620~3624.
[13] 仇春丽,陈云超,刘娜,等.超声介导自制纳米泡联合顺铂对小鼠H22肿瘤抑制作用的研究[J].中华超声影像学杂志,2016,25(2):173~177.
[14] 王辉.血必净与乌司他丁辅助治疗慢性阻塞性肺疾病急性加重期的效果比较[J].中国基层医药,2016,23(6):932~934.
[15] 王丽.类风湿关节炎患者血清白细胞介素6、白细胞介素17、粒细胞-巨噬细胞集落刺激因子和肿瘤坏死因子α水平检测的临床意义[J].中国基层医药,2016,23(16):2454~2457.
[16] 杨晓珍,张晓勇,刘海春,等.肝动脉化疗栓塞联合射频消融治疗肝癌疗效及预后分析[J].中国基层医药,2016,23(17):2609~2612.
[17] 马贵欣,MaGuixin.小剂量肝素钠联合低分子肝素钠和重组人尿激酶原治疗急性心肌梗死19例临床观察[J].中国基层医药,2016,23(14):2222~2224.
[18] 张蕴,黄文烨,张建,等.人粒细胞-巨噬细胞集落刺激因子联合R-CHOP方案治疗弥漫大B细胞淋巴瘤的临床疗效研究[J].中国基层医药,2016,23(6):805~809.